Evotec和Novo Nordisk发射LAB eN2加速器,以研制用于心肺病的药物,扩大学术伙伴关系。 Evotec and Novo Nordisk launch LAB eN² accelerator to develop drugs for cardiometabolic diseases, expanding academic partnerships.

Evotec SE和Novo Nordisk已经启动了LAB eN2药物发现加速器,最初的项目侧重于慢性肾病、代谢综合症和1型糖尿病等心血管新陈代谢疾病。 Evotec SE and Novo Nordisk have launched their LAB eN² drug discovery accelerator with initial projects focused on cardiometabolic diseases like chronic kidney disease, metabolic syndrome, and type 1 diabetes. 这些项目来自波士顿大学、哈佛大学Mass General Brigham和Joslin糖尿病中心。 The projects come from Boston University, Harvard University with Mass General Brigham, and Joslin Diabetes Center. LAB eN2正在扩大,包括波士顿儿童医院、约翰·霍普金斯大学和西奈山Icahn医学院,目的是将学术研究转化为新的药物候选人。 LAB eN² is expanding to include Boston Children's Hospital, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai, aiming to translate academic research into new drug candidates.